“We are pleased to see the completion of the acquisition of Xinheng Baide,” said Dr. Liang Qiao, Chairman and CEO of Bio-Bridge Science. “We expect Xinheng Baide to grow significantly in the future from the synergies of both parties as well as the expected increase in the demand for serum in China. Xinheng Baide fits into our strategic plan by providing a potential steady, while growing, source of revenues to us, as well as providing a new distribution channel for our products. The acquisition of Xinheng Baide represents our dedication to our strategic plan and to bringing value to our shareholders.”

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. Please refer to the Company's SEC filings for additional information.

Bio-Bridge Science, Inc.
Chris Young, 630-928-0869
cyoung@bio-bridge-science.com